Takahiro Kanai1, Takane Ito2, Jun Odaka3, Takashi Saito4, Jun Aoyagi5, Hiroyuki Betsui6, Takanori Yamagata7. 1. Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. tkanai@jichi.ac.jp. 2. Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. takane@jichi.ac.jp. 3. Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. mrjo@jichi.ac.jp. 4. Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. tk-sait@jichi.ac.jp. 5. Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. r-jun-mem@jichi.ac.jp. 6. Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. bettsu@jichi.ac.jp. 7. Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. takanori@jichi.ac.jp.
Abstract
UNLABELLED: Fabry disease is an X-linked glycosphingolipidosis caused by deficient synthesis of the enzyme α-galactosidase A, which results in accumulations of globotriaosylceramide (GL-3) in systemic tissues. Nephropathy is a dominant feature of Fabry disease. It still remains unclear how the nephropathy progresses. Recombinant agalsidase replacement therapy is currently the only approved, specific therapy for Fabry disease. The optimal dose of replacement enzyme also still remains unclear. The worldwide shortage of agalsidase-β in 2009 forced dose reduction of administration. It showed that the proteinuria emerged like surges, followed by temporary plasma GL-3 elevations in the early stages of classic Fabry disease. Additionally, it also showed that 1 mg/kg of agalsidase-β every other week could clear the GL-3 accumulations from podocytes and was required to maintain negative proteinuria and normal plasma GL-3 levels. CONCLUSION: This observation of a young patient with classic Fabry disease about 5 years reveals that the long-term, low-dose agalsidase-β caused proteinuria surges, but not persistent proteinuria, followed by temporary plasma GL-3 elevations, and agalsidase-β at 1 mg/kg every other week could clear accumulated GL-3 from podocytes and was required to maintain normal urinalysis and plasma GL-3 levels.
UNLABELLED: Fabry disease is an X-linked glycosphingolipidosis caused by deficient synthesis of the enzyme α-galactosidase A, which results in accumulations of globotriaosylceramide (GL-3) in systemic tissues. Nephropathy is a dominant feature of Fabry disease. It still remains unclear how the nephropathy progresses. Recombinant agalsidase replacement therapy is currently the only approved, specific therapy for Fabry disease. The optimal dose of replacement enzyme also still remains unclear. The worldwide shortage of agalsidase-β in 2009 forced dose reduction of administration. It showed that the proteinuria emerged like surges, followed by temporary plasma GL-3 elevations in the early stages of classic Fabry disease. Additionally, it also showed that 1 mg/kg of agalsidase-β every other week could clear the GL-3 accumulations from podocytes and was required to maintain negative proteinuria and normal plasma GL-3 levels. CONCLUSION: This observation of a young patient with classic Fabry disease about 5 years reveals that the long-term, low-dose agalsidase-β caused proteinuria surges, but not persistent proteinuria, followed by temporary plasma GL-3 elevations, and agalsidase-β at 1 mg/kg every other week could clear accumulated GL-3 from podocytes and was required to maintain normal urinalysis and plasma GL-3 levels.
Authors: Dominique P Germain; Stephen Waldek; Maryam Banikazemi; David A Bushinsky; Joel Charrow; Robert J Desnick; Philip Lee; Thomas Loew; Anouk C Vedder; Rekha Abichandani; William R Wilcox; Nathalie Guffon Journal: J Am Soc Nephrol Date: 2007-04-04 Impact factor: 10.121
Authors: Bouwien E Smid; Saskia M Rombach; Johannes M F G Aerts; Symen Kuiper; Mina Mirzaian; Hermen S Overkleeft; Ben J H M Poorthuis; Carla E M Hollak; Johanna E M Groener; Gabor E Linthorst Journal: Orphanet J Rare Dis Date: 2011-10-31 Impact factor: 4.123
Authors: Dominique P Germain; Joel Charrow; Robert J Desnick; Nathalie Guffon; Judy Kempf; Robin H Lachmann; Roberta Lemay; Gabor E Linthorst; Seymour Packman; C Ronald Scott; Stephen Waldek; David G Warnock; Neal J Weinreb; William R Wilcox Journal: J Med Genet Date: 2015-03-20 Impact factor: 6.318
Authors: Jean-Claude Lubanda; Ene Anijalg; Vladimír Bzdúch; Beth L Thurberg; Bernard Bénichou; Anna Tylki-Szymanska Journal: Genet Med Date: 2009-04 Impact factor: 8.822
Authors: Anouk C Vedder; Gabor E Linthorst; Gunnar Houge; Johannna E M Groener; Els E Ormel; Berto J Bouma; Johannes M F G Aerts; Asle Hirth; Carla E M Hollak Journal: PLoS One Date: 2007-07-11 Impact factor: 3.240
Authors: Maria Helena Vaisbich; Luís Gustavo Modelli de Andrade; Cassiano Augusto Braga Silva; Fellype de Carvalho Barreto Journal: J Bras Nefrol Date: 2022 Apr-Jun